Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China

BackgroundAs a new non-factor therapy for hemophilia A (HA), real-world study of emicizumab is still scarce. This study aimed to investigate the real-world use of emicizumab in Chinese boys with HA.MethodsPatients with moderate or severe HA were enrolled at Beijing Children's Hospital. They tak...

Full description

Bibliographic Details
Main Authors: Guoqing Liu, Kun Huang, Gang Li, Yingzi Zhen, Zhengping Li, Zhenping Chen, Runhui Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pediatrics
Subjects:
emicizumab
hemophilia a
pediatrics
prophylaxis
bleeds
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.992267/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.992267/full

Similar Items